The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.

New business premium grows 3.9% YoY. Biocon: The USFDA has classified Biocon Biologics’ Johor Bahru, Malaysia site as “Voluntary Action Indicated" (VAI). Just Dial: Q3 standalone net profit rises to ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed an inspection conducted in September 2024. BofA maintained its ...

A collection of the most-viewed Moneycontrol videos. Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting ...

Shares of Biocon soared over 4 percent on January 13 after the US Food and Drug Administration cleared arm Biocon Biologics' insulin facility in Malaysia, putting an end to a major regulatory ...

Microsoft CEO Satya Nadella announces a $3 billion investment in India's cloud and AI infrastructure, including new data centers. The company aims to train 10 million people with AI skills by 2030 ...

BRIDGEWATER, N.J., and BENGALURU, India, Jan. 9, 2025 /PRNewswire/ --Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: ...

Analyst revisions kept stocks of Zomato, Biocon, and ONGC in focus on Monday. While Zomato’s share price was down by 4.8% after Jefferies downgraded the stock to “hold”, Biocon’s share price was ...

Shares of Biocon surged over 7% in early trade on January 7, following an upgrade from international brokerage Jefferies. The firm raised its rating on Biocon to ‘underperform’ and increased its ...

Biocon stock price: At around 10:45 am, shares of the company were trading 7.22% higher at Rs 384.50 on the Bombay Stock Exchange (BSE). Listen to Story The key trigger for the rally was the US Food ...

Jefferies downgrades Zomato to "Hold," citing rising competition in q-commerce. Biocon climbs 7.8% after USFDA approval for its Stelara biosimilar and Jefferies' upgrade. ONGC gains 4.8% as CLSA ...